Non-opioid niche Target opportunity in non-opioid pain therapeutics for rare or defined patient populations, aligning with Tremeau’s focus on COX-2 selective NSAIDs and deuterium-enriched compounds like TRM-362.

Deuterium-enriched ETA Explore partnerships or licensing for TRM-362 and related deuterated etoricoxib programs to address acute pain, leveraging potential differentiation and clinically differentiated profiles.

Hemophilia pain Identify collaborations for hemophilia-related severe joint pain where a non-opioid COX-2 approach could fill an unmet need, particularly around the Vioxx generic development angle.

Strategic financings Leverage Tremeau’s prior fundraising history to propose co-development, equity financing, or milestone-based collaborations with larger pharma players seeking exposure to niche non-opioid pain assets.

Small dev agility Offer scale-friendly clinical development and regulatory support services, given the company’s lean footprint (low employee count) and early-stage product pipeline, to accelerate go-to-market for select pain indications.